GTF3C6: A Potential Drug Target and Biomarker for ALS-Like Diseases

Target Name: GTF3C6

NCBI ID: G112495

GTF3C6

GTF3C6: A Potential Drug Target and Biomarker for ALS-Like Diseases

Gene expression is a critical factor in the development and progression of many diseases, including amyotrophic lateral sclerosis (ALS). Transcription factor IIIC (TFI2C) is a key regulator of gene expression in various cell types, and its dysfunction has been implicated in the pathogenesis of many ALS-like diseases. The GTF3C6 protein, a 35 kDa subunit of TFI2C, has been identified as a potential drug target and biomarker for ALS-like diseases. In this article, we will review the current literature on GTF3C6 and its potential as a drug target and biomarker.

Expression and Functions of GTF3C6

GTF3C6 is a 35 kDa protein that is expressed in various tissues and cell types, including brain, muscle, and heart. It is a key component of the TFI2C complex, which is responsible for regulating gene expression in a variety of cell types. The TFI2C complex consists of several subunits, including GTF3C6, which functions as a negative regulator of gene expression.

GTF3C6 plays a critical role in the regulation of gene expression by binding to specific DNA sequences. It can bind to both G- and C-rich sequences, and its binding is known to be specific for certain regions of the genome. GTF3C6 has been shown to interact with other proteins, including p53, a well-known tumor suppressor protein.

In addition to its role in regulating gene expression, GTF3C6 has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and autophagy. It has been shown to promote the growth of cancer cells and to contribute to the development of neurodegenerative diseases.

Potential Drug Target

The dysfunction of GTF3C6 has been implicated in the pathogenesis of many ALS-like diseases, including ALS, a progressive neurodegenerative disease that is characterized by the progressive loss of motor neurons. The loss of GTF3C6 has been shown to contribute to the development of neurodegeneration in ALS-like diseases.

In addition to its role in the development of neurodegeneration, GTF3C6 has also been shown to contribute to the severity of ALS-like diseases. Studies have shown that higher levels of GTF3C6 are associated with a more severe phenotype of ALS-like diseases.

Biomarker

GTF3C6 has also been identified as a potential biomarker for ALS-like diseases. The loss of GTF3C6 has been shown to contribute to the development of neurodegeneration in ALS-like diseases, and it is possible that GTF3C6 levels may be a useful biomarker for the diagnosis and progression of these diseases.

Current Treatment Options

Current treatment options for ALS-like diseases are limited and have significant limitations. The progressive loss of motor neurons makes it difficult to reverse the disease, and there is a lack of effective therapies available to slow the progression of neurodegeneration.

GTF3C6 has been shown to be a potential drug target and biomarker for ALS-like diseases. By inhibiting the function of GTF3C6, it may be possible to treat these diseases and to slow the progression of neurodegeneration.

Conclusion

GTF3C6 is a protein that has been shown to play a critical role in the regulation of gene expression and the development of ALS-like diseases. Its dysfunction has been implicated in the pathogenesis of these diseases, and it is a potential drug target and biomarker. Further research is needed to understand the full role of GTF3C6 in the development and progression of ALS-like diseases, and to explore its potential as a

Protein Name: General Transcription Factor IIIC Subunit 6

Functions: Involved in RNA polymerase III-mediated transcription. Integral, tightly associated component of the DNA-binding TFIIIC2 subcomplex that directly binds tRNA and virus-associated RNA promoters

The "GTF3C6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GTF3C6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets